A weekly update on interesting numbers in product liability, class action and mass tort news from July 28–August 3. Published Fridays. Week 2 The stage of the talc trial currently going on in Los Angeles. Earlier this week, former Harvard professor John Godleski testified that he had found “numerous talc particles” in ovarian tissue removed from the plaintiff, Eva Echeverria. Godleski has testified in previous trials involving Johnson & Johnson’s talc products and in 2007 authored an article in the...Continue Reading
A weekly update on interesting numbers in product liability, class action and mass tort news from July 21–July 27. Published Fridays. 110 Brains Out of 111, the number of brains of NFL players found to have chronic traumatic encephalopathy (CTE), a degenerative brain disease. In research published this week in the Journal of the American Medical Association, neuropathologist Dr. Ann McKee and colleagues studied over 200 brains from deceased football players. Although Dr. McKee admits that there is a selection...Continue Reading
A weekly update on interesting numbers in product liability, class action and mass tort news from July 14–July 20. Published Fridays. 33% The percent of increased risk for ovarian cancer claimed in a class action suit against Johnson & Johnson’s talc products, dismissed Monday. Johnson & Johnson and their talc supplier Imerys had been criticized for not disclosing the risk of ovarian cancer associated with their talc products, including Baby Powder and Shower to Shower. A judge told Mona Estrada,...Continue Reading
A weekly update on interesting numbers in product liability, class action and mass tort news from July 7–July 13. Published Fridays. $3.3 billion The sales of Bristol-Myers Squibb and Pfizer’s Eliquis, a significant portion of the $10 billion anticoagulant market. This week, plaintiffs related to a man who died after taking Eliquis accused Bristol-Myers and Pfizer of failing to adequately test the drug and not advertising that the drug had no known antidote. The claims against Eliquis are similar to...Continue Reading
In new research published in JAMA Internal Medicine, Dr. Satyajit Reddy and colleagues show that following a 2010 FDA advisory concerning inferior vena cava (IVC) filters, implantation of IVC filters decreased in the United States. In 2010, research by Nicholson et al. revealed that Bard Recovery and Bard G2 IVC filters had a high risk of cracking and breaking off into the body, causing life-threatening risks. After the FDA received 921 adverse event reports of problems with IVC filters similar...Continue Reading
Speak with a Lawyer
Contact an attorney today for a free and confidential legal consultation.